ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,313.24
0.10%
US Tech 100
18,158.00
-0.21%
다우존스 지수
39,869.67
0.16%
Bitcoin
70,879.97
-0.81%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Windtree Therapeutics Inc (WINT)

  7. Windtree Therapeutics Inc (WINT) 뉴스

WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:WINT
일자시간출처헤드라인심볼기업
2024/05/1605:59Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:WINTWindtree Therapeutics Inc
2024/05/0921:41Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
2024/05/0721:00GlobeNewswire Inc.Windtree Therapeutics Regains Compliance with NasdaqNASDAQ:WINTWindtree Therapeutics Inc
2024/04/1821:00GlobeNewswire Inc.Windtree Therapeutics Announces Reverse Stock SplitNASDAQ:WINTWindtree Therapeutics Inc
2024/04/1721:00GlobeNewswire Inc.Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
2024/04/0905:48GlobeNewswire Inc.Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingNASDAQ:WINTWindtree Therapeutics Inc
2024/02/1707:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
2024/02/1507:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
2024/02/1506:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
2024/02/1410:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
2024/02/1306:40Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
2024/02/0207:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:WINTWindtree Therapeutics Inc
2024/02/0122:00GlobeNewswire Inc.Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchNASDAQ:WINTWindtree Therapeutics Inc
2024/01/3122:40InvestorsHub NewsWireWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesNASDAQ:WINTWindtree Therapeutics Inc
2024/01/3122:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
2024/01/3122:00GlobeNewswire Inc.Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesNASDAQ:WINTWindtree Therapeutics Inc
2024/01/2523:04InvestorsHub NewsWireWindtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyNASDAQ:WINTWindtree Therapeutics Inc
2024/01/2522:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
2024/01/2522:30GlobeNewswire Inc.Windtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyNASDAQ:WINTWindtree Therapeutics Inc
2024/01/2306:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
2024/01/1722:00GlobeNewswire Inc.Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionNASDAQ:WINTWindtree Therapeutics Inc
2024/01/1721:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
2024/01/1706:16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
2024/01/0306:05GlobeNewswire Inc.Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorNASDAQ:WINTWindtree Therapeutics Inc
2023/12/1822:00GlobeNewswire Inc.Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
2023/11/1622:00GlobeNewswire Inc.Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator PatentNASDAQ:WINTWindtree Therapeutics Inc
2023/11/1401:41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:WINTWindtree Therapeutics Inc
2023/11/1006:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
2023/11/1006:15GlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
2023/11/1006:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
 검색 관련기사 보기:NASDAQ:WINT

최근 히스토리

FX
USDEUR
US Dollar vs Euro
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
NYSE
CVX
Chevron
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
CCOM
SILVER
SILVER
NYSE
XOM
Exxon Mobil
NYSE
MRK
Merck
NYSE
AXP
American Express
NYSE
DIS
Walt Disney
COIN
ETHUSD
Ethereum
FX
USDJPY
US Dollar vs Yen
PM
XAUUSD
Gold vs US Dollar
NASDAQ
NVDA
NVIDIA
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유